GNW-Adhoc: ONWARD plans webcast to provide business update for H1 2023

^Eindhoven, Sept 05, 2023 (GLOBE NEWSWIRE) — ONWARD Medical NV (Euronext:

ONWD), the medical technology company bringing innovative therapies to

Restoring movement, function, and independence in people with

Spinal Cord Injury developed announced today that there will be a webcast

to present its business highlights for the half-year 2023

discuss.

The webcast will take place on September 19, 2023 at 2pm CET / 8am ET.

It will be moderated by CEO Dave Marver and CFO Lara Smith Weber

Discuss highlights of the 2023 half-year and give a business update.

To participate in the webcast via Zoom, please register via this

Link (https://onwd.zoom.us/webinar/register/WN_q8A4aB4_TiKAUn3tJ6t84g).

Participants can also be connected by telephone:

+32 2 290 9360 (Belgium)

+49 69 3807 9884 (Germany)

+31 20 794 0854 (Netherlands)

+41 22 591 0156 (Switzerland)

+44 203 481 5240 (UK)

+1 346 248 7799 (US)

Other phone numbers available

(https://us02web.zoom.us/zoomconference?m=ODQwMDc2ODQ3NDU.4Z9dvTMoCvaEym4uZVHhEo

kjpEutPTPB&_x_zm_rtaid=bZlEbl_NSXC-

Td9ETD5uUg.1666686155946.2fb4a8093478ce9dedddbf91807a4829&_x_zm_rhtaid=97)

Webinar ID: 884 9100 3320

A replay of the webcast will follow the live event

(https://ir.onwd.com/financial-information) on the company’s website

be available.

About ONWARD Medical

ONWARD is a medical technology company that provides therapies for recovery

of movement, function and independence in people with

developed spinal cord injuries and restricted mobility. Based on

more than a decade of scientific and preclinical research conducted in

the company has conducted in leading neuroscience laboratories

nine breakthrough device designations from the US Food and Drug Administration

for its ARC Therapy Platform(TM).

ONWARD® ARC Therapy, performed with external ARC-EX(TM) or implantable ARC-IM

Systems(TM) is designed to provide a targeted,

enable programmed spinal cord stimulation. In 2023 became positive

Results of the company’s pivotal study called Up-LIFT

presented in the ability to improve transcutaneous ARC therapy

the strength and function of the upper extremities was assessed. The company

is preparing to submit regulatory submissions for ARC-EX in the US

and Europe before. In parallel, the company conducts studies with its

implantable ARC-IM platform through 2022 positive preliminary

clinical results for improved blood pressure regulation after a

showed spinal cord injury. Other ongoing studies deal with the

combined use of ARC-IM with a brain-computer interface

(BCI).

ONWARD is headquartered in Eindhoven, The Netherlands and has a

Science and Development Center in Lausanne, Switzerland and a US office in

Boston, Mass. The company also maintains an academic

partnership with. NeuroRestore, a collaboration between the

Swiss Federal Institute of Technology (EPFL) and the University Hospital

Lausanne (CHUV).

For more information visit ONWD.com and

(http://www.onwd.com/)connect with us on LinkedIn

(https://www.linkedin.com/company/onwdempowered/) and YouTube

(https://www.youtube.com/@ONWARD_EMPOWERED/videos).

waiver

Certain statements, beliefs and opinions contained in this press release are

forward-looking and reflect the current expectations and forecasts of the

company or the directors of the company with respect to future

events reflected. By their nature, forward-looking statements include several

Risks, uncertainties and assumptions that may cause the

actual results or events differ materially from those set forth in the

results expressed or implied by any forward-looking statement; or

events differ. These risks, uncertainties and assumptions may change

detrimental to earnings and the financial impact of here

plans and events described. A variety of factors

including but not limited to changes in demand,

Competition and technology can cause the actual

Events, performance or results differ significantly from anticipated developments

differ. The forward-looking statements contained in this press release

Statements regarding past trends or activities should not be taken as a representation

be understood that such trends or activities will occur in the future

will continue. As a result, the company expressly disclaims any

Obligation or obligation from, updates or revisions of

to release any forward-looking statements in this press release that

arise from a change in expectations or a change in events,

Conditions, assumptions or circumstances upon which these forward-looking statements are based

statements are based. Neither the Company nor its advisers or agents, nor

any of its subsidiaries or its officers or employees

such a person guarantee that the assumptions made by such

underlying forward-looking statements are free of errors, and none

of them accepts responsibility for the future correctness of the in

forward-looking statements contained in this press release or the

actual occurrence of the forecast developments. You should yourself

not place undue reliance on forward-looking statements, which are made only as of the date

of the publication of this press release. All ONWARD products and

-therapies referred to herein, including but not limited to

limited to ARC-IM, ARC-EX and ARC-Therapy, are under investigation and

are not available for commercial use.

°

ttn-28